Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00869999 · ClinicalTrials.gov registry record · Phase 2
Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00869999: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00869999 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00869999, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
Everolimus is an oral mTOR inhibitor with demonstrated preliminary efficacy and safety in diffuse large B-cell lymphoma (DLBCL) in both preclinical and clinical studies. The purpose of this research study is to determine whether Everolimus plus rituximab is safe and effective in participants with relapsed or refractory DLBCL. Everolimus is an investigational drug that works by blocking a special protein that helps cancer cells grow. The safety and effectiveness of Everolimus in the treatment of DLBCL has not yet been fully determined and is still investigational. The other drug in this study, rituximab, is approved by the US Food and Drug Administration (FDA) for use in patients who have diffuse large B-cell lymphoma and certain other types of non-Hodgkin lymphoma. Rituximab is a drug that destroys both normal and cancerous B-cells.
Interventions
- DRUG Everolimus
- DRUG rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00869999
The ClinicalTrials.gov registry entry for NCT00869999 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT00869999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00869999 about?
NCT00869999 is a clinical study titled "Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma". Everolimus is an oral mTOR inhibitor with demonstrated preliminary efficacy and safety in diffuse large B-cell lymphoma (DLBCL) in both preclinical and clinical studies. The purpose of this research study is to determine whether Everolimus plus rituximab is safe and effective in participants with re...
What is the current status of trial NCT00869999?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2009-05. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00869999?
The interventions under investigation include: Everolimus (DRUG), rituximab (DRUG).
Who is sponsoring clinical trial NCT00869999?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.